Revance Reports Positive 6-Month Duration in BELMONT Study
29 oct. 2015 07h00 HE
|
Revance Therapeutics, Inc
– 6-month duration of effect is statistically significant compared to BOTOX® Cosmetic –
– All dose levels of RT002 achieved highly statistically significant,...
Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia
29 sept. 2015 16h02 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines
28 sept. 2015 16h02 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
09 sept. 2015 16h02 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Releases Second Quarter 2015 Results
06 août 2015 16h02 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
Revance Therapeutics to Release Second Quarter 2015 Financial Results Thursday, August 6, 2015
23 juil. 2015 16h02 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., July 23, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.
02 juil. 2015 16h06 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., July 2, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate
03 juin 2015 07h30 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., June 3, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance to Participate in Upcoming Investor Conferences
21 mai 2015 08h30 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Releases First Quarter 2015 Financial Results
13 mai 2015 16h05 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...